Record Revenue Levels and Preparations On-Track for Further Expansion Management to Host Conference Call at 7:30 a.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced financial results for the three and nine […]
Author: Ken Dropiewski
Okami Medical Announces Major Milestones: FDA 510(k) Clearance And Key Patent For The LOBO Vascular Occluder
Microcatheter-delivered device designed to provide rapid and focal occlusion of a wide range of peripheral arterial targets ALISO VIEJO, Calif., Nov. 4, 2019 /PRNewswire/ — Okami Medical Inc., a medical device company, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and initial launch of the LOBOTM Vascular Occlusion System. […]
CORRECTING and REPLACING PHOTO PQ Bypass Initiates Pivotal Study of Next-Generation Advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease
MILPITAS, Calif.–(BUSINESS WIRE)–Please replace the photo with the accompanying corrected photo. The release reads: PQ Bypass, Inc., a clinical-stage medical device company, today announced it has enrolled the first patient in its TORUS 2 multi-center clinical trial of its self-expanding TORUS® stent graft system, a novel technology designed for the […]
GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use
Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products CHALFONT ST GILES, England–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, […]
Shockwave Announces Commercial Availability of Below-the-Knee IVL Catheter
Shockwave S4 Catheter Expands the Intravascular Lithotripsy System Portfolio to Address the Challenges of Critical Limb Ischemia SANTA CLARA, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced commercial availability of […]
Correvio Announces FDA Advisory Committee Meeting to Review Brinavess™ for Recent Onset Atrial Fibrillation
VANCOUVER, Nov. 4, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) will hold a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting in connection with its review of the pending New Drug […]
Cook Medical India Opens New Facility in Chennai
CHENNAI, India–(BUSINESS WIRE)–Cook Medical India celebrated its new office opening. The company has shifted to a modern, 20,000-square foot office at Kochar Jade in Guindy, Chennai. It is located at the city’s major business district with easy access to land and air freight stations. India is an important part of […]
Ra Medical Systems Announces Substantial Completion of Audit Committee Investigation
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today announced that the Audit Committee of the Board of Directors (the “Audit Committee”) has substantially completed its internal investigation, which was originally announced in August. […]
SignPath Pharma, Inc. Announces an Out-license Agreement of Its CorreQTTM Technology for Mitigation of QT Prolongation with Rain Therapeutics Inc.
SALT LAKE CITY–(BUSINESS WIRE)–SignPath Pharma (Salt Lake City UT) today announced the first commercial out-license of its proprietary CorreQT technology platform. SignPath entered into an agreement with Rain Therapeutics (Newark CA), which licenses SignPath’s CorreQT technology for use in conjunction with Rain’s proprietary lead compound, Tarlox® (tarloxotinib,) a potent pan-ErbB […]
Proteon Therapeutics Announces Third Quarter 2019 Financial Results
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended September […]



